2021 Transparency Report

GSK’s voluntary decision to publish our payments to HCPs and HCOs is part of our commitment to greater transparency and high ethical standards in our business practices. The “Voluntary Framework on Disclosure” was developed by Innovative Medicines Canada.

Aggregate payments (one sum total)

$1,719,789*

TOV to HCPs

$5,150,401

TOV to HCOs

*View a breakdown of individual payments made to HCPs.

Other figures

$774,361,177

2021 GSK in Canada Sales
(Total Payments to HCPs and HCOs represent 0.89% of Sales)

$690,744

2021 Community Groups Grants and Donations
GSK also provides and publishes funding made to patient groups.

For clarity purposes only, please note the following:

  • Applicable taxes may be included or excluded.
  • The amounts provided may include certain related incidental expenses (such as, but not limited to, mileage reimbursement for travel).
  • HCPs engaged by GSK who appear in the individual payments section have consented to disclosure of their names and payments. Pursuant to Canadian privacy law, consent to the individual disclosure of information may be withdrawn at any time.
  • GSK has used its reasonable best efforts to capture the most comprehensive data possible according to its knowledge and interpretation of the Voluntary Framework of Payments to HCPs/HCOs.

NOTE: While GSK makes every effort to present accurate and reliable information, GSK makes no warranty and assumes no legal liability or responsibility for the accuracy or completeness of the information contained herein. GSK shall not be liable for damages resulting from the use or misuse of the information contained on this website. Certain links may lead to resources located on servers that are not maintained by GSK or under its control, and such hypertext links are provided as a convenience only. The inclusion of a link does not imply endorsement by or of the referenced site and GSK is not responsible for the contents of or the availability of access to such websites.